Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Association of periodontitis with cognitive decline and its progression: Contribution of blood‐based biomarkers of Alzheimer's disease to this relationship

  • Carballo, Álvaro
  • López‐Dequidt, Iria
  • Custodia Malvido, Antía
  • Botelho, João
  • Aramburu Núñez, Marta
  • Machado, Vanessa
  • Pías‐Peleteiro, Juan Manuel
  • Ouro Villasante, Alberto
  • Romaus-Sanjurjo, Daniel
  • Vázquez‐Vázquez, Laura
  • Jiménez‐Martín, Isabel
  • Aguiar Fernández, Pablo
  • Rodríguez‐Yáñez, Manuel
  • Aldrey Vázquez, José Manuel
  • Blanco Carrión, Juan
  • Castillo Sánchez, José Antonio
  • Sobrino, Tomás
  • Leira Feijóo, Yago
Aim To assess whether periodontitis is associated with cognitive decline and its progression as well as with certain blood-based markers of Alzheimer's disease. Materials and Methods Data from a 2-year follow-up prospective cohort study (n = 101) was analysed. Participants with a previous history of hypertension and aged ≥60 years were included in the analysis. All of them received a full-mouth periodontal examination and cognitive function assessments (Addenbrooke's Cognitive Examination (ACE) and Mini-Mental State Examination [MMSE]). Plasma levels of amyloid beta (Aβ)1-40, Aβ1-42, phosphorylated and total Tau (p-Tau and t-Tau) were determined at baseline, 12 and 24 months. Results Periodontitis was associated with poor cognitive performance (MMSE: β = −1.5 [0.6]) and progression of cognitive impairment (hazard ratio [HR] = 1.8; 95% confidence interval: 1.0–3.1). Subjects with periodontitis showed greater baseline levels of p-Tau (1.6 [0.7] vs. 1.2 [0.2] pg/mL, p < .001) and Aβ1-40 (242.1 [77.3] vs. 208.2 [73.8] pg/mL, p = .036) compared with those without periodontitis. Concentrations of the latter protein also increased over time only in the periodontitis group (p = .005). Conclusions Periodontitis is associated with cognitive decline and its progression in elderly patients with a previous history of hypertension. Overexpression of p-Tau and Aβ1-40 may play a role in this association
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Periodontitis is associated with subclinical cerebral and carotid atherosclerosis in hypertensive patients: A cross‑sectional study

  • Vázquez Reza, María
  • López Dequidt, Iria Alejandra
  • Ouro Villasante, Alberto
  • Iglesias Rey, Ramón
  • Campos Pérez, Francisco
  • Blanco Carrión, Juan
  • Rodríguez Yáñez, Manuel
  • Castillo Sánchez, José Antonio
  • Sobrino Moreiras, Tomás
  • Leira Feijóo, Yago
Objective: To examine the relationship between periodontitis and subclinical intracranial atherosclerosis. The association of periodontitis with preclinical markers of atherosclerosis in other vascular territories was also explored. Material and methods: This was a cross-sectional study where 97 elderly subjects with a previous history of hypertension received an ultrasonographic evaluation to assess subclinical atherosclerosis in different vascular territories: (1) cerebral [pulsatility (PI) and resistance index (RI) of the middle cerebral artery], (2) carotid [intima-media thickness (IMT)], and (3) peripheral [ankle-brachial index (ABI)]. Additionally, participants underwent a full-mouth periodontal assessment together with blood sample collection to determine levels of inflammatory biomarkers (leukocytes, fibrinogen, and erythrocyte sedimentation rate), lipid fractions (total cholesterol and high- and low-density lipoprotein), and glucose. Results: Sixty-one individuals had periodontitis. Compared to subjects without periodontitis, those with periodontitis showed higher values of PI (1.24 ± 0.29 vs 1.01 ± 0.16), RI (0.70 ± 0.14 vs 0.60 ± 0.06), and IMT (0.94 ± 0.15 vs 0.79 ± 0.15) (all p < 0.001). No statistically significant differences were found neither for ABI or for other clinical and biochemical parameters. An independent association was found between periodontitis and increased intracranial atherosclerosis (ORadjusted = 10.16; 95% CI: 3.14-32.90, p < 0.001) and to a lesser extent with thicker carotid IMT (ORadjusted = 4.10; 95% CI: 1.61-10.48, p = 0.003). Conclusions: Periodontitis is associated with subclinical atherosclerosis in both intracranial and carotid arteries in elderly subjects with hypertension. Clinical relevance: The association of periodontitis with intracranial atherosclerosis implies that periodontitis patients might have greater chances to develop ischemic stroke in the future
Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publicación Artículo científico (JournalArticle)

Alzheimer’s disease seen through the eye: ocular alterations and neurodegeneration

  • Romaus-Sanjurjo, Daniel
  • Regueiro, Uxía 
  • López López, Maite
  • Vázquez Vázquez, Laura
  • Ouro, Alberto
  • Lema Gesto, María Isabel
  • Sobrino, Tomás
Alzheimer’s Disease (AD) is one of the main neurodegenerative diseases worldwide. Unfortunately, AD shares many similarities with other dementias at early stages, which impedes an accurate premortem diagnosis. Therefore, it is urgent to find biomarkers to allow for early diagnosis of the disease. There is increasing scientific evidence highlighting the similarities between the eye and other structures of the CNS, suggesting that knowledge acquired in eye research could be useful for research and diagnosis of AD. For example, the retina and optic nerve are considered part of the central nervous system, and their damage can result in retrograde and anterograde axon degeneration, as well as abnormal protein aggregation. In the anterior eye segment, the aqueous humor and tear film may be comparable to the cerebrospinal fluid. Both fluids are enriched with molecules that can be potential neurodegenerative biomarkers. Indeed, the pathophysiology of AD, characterized by cerebral deposits of amyloid-beta (Aβ) and tau protein, is also present in the eyes of AD patients, besides numerous structural and functional changes observed in the structure of the eyes. Therefore, all this evidence suggests that ocular changes have the potential to be used as either predictive values for AD assessment or as diagnostic tools.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Intracerebroventricular phospho-tau immunotherapy alleviates cortical phospho-tau burden and motor phenotype in a neuron-specific P301S tauopathy mouse

  • Kemppainen, S.
  • Aramburu-Núñez, M.
  • Koivisto, H.
  • Posado-Fernández, A.
  • Felix-Garcia, M. R.
  • Nurminen, K.
  • Häkli, S.
  • Abelli-Deulofeu, E.
  • Kaisto, M.
  • Custodia, A.
  • van Olst, L.
  • Willman, R-M
  • Mäkinen, P.
  • Miettinen, P. O.
  • Schouten, M.
  • Iglesias-Rey, Ramón
  • Kamermans, A.
  • Martiskainen, H.
  • Rauramaa, T.
  • de Vries, H. E.
  • Eng, E.
  • Salo, R.
  • Kettunen, M.
  • Gröhn, O.
  • Gureviciene, I.
  • Chmielevski, P.
  • Ouro, A.
  • Lapresa, Rebeca
  • Agulla, Jesús
  • Almeida, Angeles
  • Doria, G.
  • Flores, O.
  • Aguiar, P.
  • Carmans, S.
  • Roucourt, B.
  • Hiltunen, M.
  • Sobrino, T.
  • Tanila, H.
Pathological tau accumulation disrupts neuronal function, leading to neurodegeneration and dementia in tauopathies, such as Alzheimer's disease and frontotemporal dementia. Despite the progression of several anti-tau therapies to clinical trials, no disease-modifying treatments for tauopathies exist. Tau hyperphosphorylation is a key factor in pathology progression. Among all tau phosphorylation sites targeted in preclinical passive immunization studies, the classic AT8 pathological tau phosphorylation sites have remained understudied. Thus, we investigated the potential of immunotherapy against phosphorylated tau (pTau) in a P301S mouse model of tauopathy. We administered a new monoclonal B6 antibody that targets tau phosphorylation sites at serine 202, threonine 205 and serine 208 either systemically for 3 months or locally into the cerebral ventricles for 1 or 2 months via an osmotic minipump. Systemic administration failed to reach the brain effectively, and subsequently, was not able to alleviate the progressive motor impairment seen in this tauopathy mouse model. By contrast, intraventricular administration improved motor function in earlier stages of pathology but had a lesser effect in later stages. The local administration for 8 weeks reduced the number of pTau positive neurons in cortex and hippocampus. Our findings indicate that targeting the classical pathological tau phosphorylation sites can ameliorate tau pathology and improve function in a mouse tauopathy model. These results add to growing evidence supporting the efforts in developing tau-targeting immunotherapies for neurodegenerative diseases associated with pathological tau deposits., This research was funded by the European Union, Horizon 2020 project PANA, grant number 686009, Academy of Finland (grant numbers 338182, 307866, 315459, and 330178, 339767); the Sigrid Jusélius Foundation (SJ-2022) and the Strategic Neuroscience Funding of the University of Eastern Finland (NEURO-RC-2019). A.P-F.'s grant was funded by the European Union's FP7 Marie-Curie Initial Training Network program (grant agreement 606950). This study was also funded by grants from the Xunta de Galicia (IN607A2022/07), Instituto de Salud Carlos III (ISCIII) (PI22/00938, PI21/00727, CIBERNED CB22/05/00067, and RD21/0006/0005) and Ministerio de Ciencia e Innovación (RTC2019-007373-1 and PDC2022-134000-I00). Furthermore, this study was also supported by grants from the INTERREG Atlantic Area (EAPA_791/2018_NEUROATLANTIC project), INTER-REG V A España Portugal (POCTEP) (0624_2IQBIONEURO_6_E), and the European Regional Development Fund (ERDF). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript., Peer reviewed